Age>60 years (p<0.001), male (p<0.001), diabetes (68%) and hypertension (59%) were associated with SA. Most patients with SA were sleepy (Epworth >10).
Results:
In patients without NOT, there was no significant difference between baseline and the sixth month. In NOT patients, a marked AHI reduction was observed between baseline versus the first night and the sixth month, respectively, 36.8±2.6 versus 20.8±3.0 and 18.3±2.4 events/h (p<0.0001) and related to a central AHI decrease, respectively, 23.3±2.8 versus 8.3±1.6 and 6.1±1.4 events/h (p<0.0001). The oxygen desaturation index (ODI) evolved similarly: 33.0±5.2 versus 7.5±0.5 and 9.3±2.6 events/h (p<0.0001). NOT had no effects on obstructive and mixed AHI. In NOT patients versus those without, respectively, AHI decreased by 49.0±6.0% versus increased by 2.0±14.0% (p<0.0001), ODI decreased by 59.0±9.4% versus 6.4±14.7% (p=0.004), SaO 2 <90% time decreased by 61.4±9.9% versus increased by 60.0±68.4% (p=0.1) and LVEF increased by 14.5±10.2% versus 5.6±16.1% (p=0.6).
Conclusions:
In stable CHF patients, NOT significantly reduced central AHI and ODI, with acute effects being sustained over time and impacting neither obstructive and mixed AHI nor daytime LVEF.
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Treatment of heart failure in the real life: clinical inertia early after discharge worsens outcome
Emmanuelle Berthelot-Garcias (1), Richard Isnard (2), Thibaud Damy (3), Erwan Donal (4), Michel Galinier (5), Jean-Noel Trochu (6), Jean Jacques Dujardin (7), Genevieve Mulak (8), Damien Logeart (1) (1) Hôpital Lariboisière, cardiologie, Paris, France -(2) Hôpital Pitié Salpétrière, Paris, France -(3) Hôpital Henri Mondor, Créteil, France -(4) CHU Rennes, Rennes, France -(5) CHU Toulouse, Toulouse, France -(6) CHU antes, antes, France -(7) CH Douai, Douai, France -(8) SFC, Paris, France Background: After acute decompensated heart failure (ADHF), most patients are often early discharged before treatment optimization. Following months are important to optimize the treatment. We analyzed treatments at discharge and at 3 months after discharge and the impact on outcome in patients with heart failure and reduced left ventricular ejection fraction (HF-REF).
Methods: French Society of Cardiology conducted a one-day national survey in a randomized sample of 170 hospitals. All hospitalized patients with a confirmed diagnosis of ADHF were included. Datas were recorded during both hospitalizations and one-year follow up.
Results: Treatment informations at discharge as well as at 3 months were obtained in 519 patients (age 72±14y, 34% females). At discharge, loop diuretics were prescribed in 89% cases with daily dose of 87±146 mg, ACE-I or ARB in 80% cases with daily dose reaching 36±31% of target dose, beta blocker (BB) in 70% with daily dose of 27±51% of target dose, aldosterone antagonists (AA) in 23% and digoxin in 9%. At 3 months, there was only few changes in mean rates of prescriptions as compared to discharge (Table) . Clinical characteristics significantly associated with the lack of prescription at 3 months were creatininemia >15 mg/l for ACE-I/ARB, BB and AA, LVEF >30% for BB and AA, and also COPD for BB.
All-cause-mortality at 12 months was 19% with marked differences according to prescription or not of ACE-I/ARB at 3 months (15 vs 29%, p=0.002) as well as BB (15 vs 27%, p=0.008). After adjustment on clinical characteristics (age, blood pressure, creatininemia, LVEF, natriuretic peptides, COPD, diabetes), lack of treatment at 3 months was an independant predictor of mortality especially ACE-I or ARB , p 0.005).
Conclusion: Individual treatments are poorly optimized after discharge. Such inertia leads to poor outcome, that suggests a room to improve HF management in the practice, especially in the 3 months after discharge. 
